Check out which companies are making headlines after the bell on Thursday.
Fossil Group Inc., down $3.39 to $19.48. Procter& Gamble Co., up $3.26 to $91.12. Humana Inc., down 65 cents to $205.32.
Equities in the United States climbed to new highs on Wednesday as investors parsed through key economic data.
PepsiCo, Merck, and Apple stocks are making headlines this Wednesday morning before the opening bell.
KENILWORTH, N.J.— Merck& Co. will stop its study of an experimental Alzheimer's drug in people with mild or moderate symptoms because interim results showed "virtually no chance" of any benefit. However, the drugmaker said Tuesday it will continue another study of the drug, verubecestat, in patients who don't yet show symptoms. While a few treatments temporarily...
Merck stops their Alzheimer's drug trial due to "no chance of finding a positive clinical effect." CNBC's Meg Tirrell reports. The “Fast Money” traders weigh in.
The Dow Jones industrial average is off to a solid start in 2017 thanks in large part to just four of its 30 components.
U.S. equities fell as worries about the White House's policy agenda lingered, while earnings season continued.
Stocks closed mostly flat as investors looked ahead to Friday's jobs report, amid growing tensions between the US and other global powers.
Some of the names on the move ahead of the open.
Merck, Facebook, and Macy's stocks are making headlines this Thursday morning before the opening bell.
Markets will be setting up for Friday's jobs report Thursday as investors await another batch of earnings reports, including Amazon.com.
U.S. equities closed mostly higher on Wednesday after the Federal Reserve kept interest rates unchanged, as was widely expected.
There are buying opportunities in biotech and drug stocks despite the backlash from the repeal of Obamacare.
CNBC's Meg Tirrell reports on President Trump's meeting with big pharmaceutical CEOs, and how it is impacting the biotech sector. The "Fast Money" traders weigh in.
U.S. equities traded mixed as investors continued to evaluate the latest policies from the White House.
Tony Coles, Yumanity Therapeutics CEO, former Onyx CEO, weighs in on President Trump's drug pricing rhetoric and meeting with pharma leaders. With CNBC's Meg Tirrell.
Ronald Klain, former White House senior advisor, and Vamil Divan, Credit Suisse pharma analyst, weigh in on President Trump's plans to bring down drug prices and the potential impact on the pharmaceutical industry. With CNBC's Meg Tirrell.
"We have to get the prices down," Trump tells drugmakers at the White House.
Stocks notched their worst day of 2017, as a new measure taken by the Trump administration on immigration sent jitters through the market.